Recent advances in drug discovery research have led to the development of numerous drug candidate compounds with high ...

Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival ...

A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how ...

Givastomig is designed to simultaneously target CLDN18.2 and 4-1BB. CLDN18.2 is a tight junction protein that is typically ...

Nanomedicine is rapidly transforming the landscape of cancer treatment through the development of advanced drug-delivery carriers. Despite notable progress ...